New-onset diabetes after transplantation in tacrolimus-treated, living kidney transplantation: long-term impact and utility of the pre-transplant OGTT
Fasting plasma glucose before
NODAT usually occurs early after transplantation, and is usually diagnosed according to general population guidelines
However, an adverse effect of KT is post-transplant diabetes mellitus (PTDM)
It was not until 2003 that guidelines established diagnosis and management recommendations for new-onset diabetes after transplantation Effect of everolimus with low-dose tacrolimus on development of new-onset diabetes after transplantation and allograft function in kidney transplantation: a multicenter, open-label, randomized
New-onset diabetes mellitus after transplantation (NODAT) is a frequent complication in kidney allograft recipients
In this study, we found that the incidence of NODM is TAC concentration (cTAC)-dependent
Methods: We retrospectively analyzed the data of 973 liver transplant recipients between March 1999 and September 2014 in West China Hospital Liver Transplantation Center
Transplant Background: New-onset diabetes after transplantation (NODAT) is an important complication after kidney transplantation
Although there is no novel finding in the study, it is nicely performed and written
New onset diabetes mellitus after transplantation has been reported to occur in 4% to 25% of renal transplant recipients, 2
This study included 168 non-diabetic patients (58% males, 69% of Chinese ethnicity) who received
Effect of Everolimus with Low-Dose Tacrolimus on Development of New-Onset Diabetes After Transplantation and Allograft Function in Kidney Transplantation: A Multicenter, Open-Label, Randomized Trial The 2003 International Consensus Guidelines defined new-onset diabetes after transplantation
For Protocol A, the patient was administered 20 mg basiliximab pretransplantation and at 4 d posttransplantation; these patients also received